Press release
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California. The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal (CRC), esophageal, gastric and anal cancers, in a total of five presentations.\n\n“On the heels of the groundbreaking CIRCULATE-Japan results just released, we are excited to share additional data further underscoring the real-world utility of Signatera in GI cancers,” said Solomon Moshkevich, general manager of oncology at Natera. “This data continues to reinforce the value of personalized and tumor-informed MRD testing across different treatment settings.”\n\nStacey A. Cohen, M.D., of the University of Washington and the Fred Hutchinson Cancer Center, will deliver an oral presentation on a real-world study of 14,425 patients with stage I-III CRC after surgery. The preliminary findings from this study suggest that though cfDNA concentration is significantly increased in the first 2-4 weeks, Signatera detection rates remained consistent with those of weeks 4-8, indicating that standard MRD testing windows could start two weeks after surgery.\n\n“Through our study, we’ve shown for the first time in a large, real-world setting that MRD testing with Signatera could be performed starting at 2 weeks, without compromising test sensitivity,” said Dr. Cohen, author and presenter of the study. “These findings highlight the potential for oncologists and patients to benefit from earlier opportunities to consider Signatera to inform personalized treatment for patients with colorectal cancer.”\n\nThe full list of Signatera presentations and activities during ASCO GI is below.\n\nOral presentations\n\n\nJan. 21, 11:10 AM PT | Stage I-III colorectal cancer (Oral Presentation)\nPresenter: Stacey A. Cohen, M.D., University of Washington and the Fred Hutchinson Cancer Center\nKinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer\n\n...